Celera has named Wayne Roe as a director of the company. Roe is a general partner for medical technology fund DFJ In-Cube Ventures. He also currently sits on the executive committee of the Maryland Angels Fund as well as the board of directors of ISTA Pharmaceuticals. Roe previously was chairman of Covance Health Economics and Outcomes Services.
Genomic Health said that it has appointed Ginger Graham to its board of directors. Graham is a former president and CEO of Amylin Pharmaceuticals. Prior to that role, she was group chairman in the office of the president, at Guidant. She also has held a number of management positions at Eli Lilly.
Anne Wojcicki, co-founder of 23andMe, has been named to the board of directors of the Foundation for the National Institutes of Health. She was one of five new directors announced last week. The others are Pfizer Chief Medical Officer Joseph Feczko; Peter Neupert, corporate vice president of the Health Solutions Group at Microsoft; Kurt Schmoke, dean of Howard University School of Law; and Samuel Thier, professor emeritus, medicine, and health care policy at Harvard Medical School and Massachusetts General Hospital.
Affymetrix said that Vernon Loucks will retire from its board of directors effective Jan. 1, 2009. His spot on the board will be filled by Affymetrix President and CEO Kevin King.
In addition, Affy disclosed in a filing with the US Securities and Exchange Commission that King will receive an increase in his annual base salary to $675,000 from $500,000. He also will be eligible for a target cash bonus of 75 percent of his annual salary.